Librandi v. Alexion Pharmaceuticals Inc

CourtDistrict Court, D. Connecticut
DecidedJune 14, 2023
Docket3:22-cv-01126
StatusUnknown

This text of Librandi v. Alexion Pharmaceuticals Inc (Librandi v. Alexion Pharmaceuticals Inc) is published on Counsel Stack Legal Research, covering District Court, D. Connecticut primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Librandi v. Alexion Pharmaceuticals Inc, (D. Conn. 2023).

Opinion

UNITED STATES DISTRICT COURT DISTRICT OF CONNECTICUT

SUSANNA LIBRANDI,

Plaintiff,

v. No. 3:22cv1126(MPS) ALEXION PHARMACEUTICALS, INC.,

Defendant.

RULING ON MOTION TO DISMISS In response to the COVID-19 pandemic, Susanna Librandi's employer, Alexion Pharmaceuticals, Inc., required its employees to be vaccinated against COVID-19. Employees could request an exemption to the vaccination mandate; if the employee's request was granted, the employee was required to test weekly for coronavirus. Librandi initially requested, and was granted, a religious exemption but she later withdrew her request for an exemption. As a result, she was required to comply with Alexion's mandatory COVID-19 vaccination requirement. When Librandi failed to do so, Alexion terminated her employment for noncompliance with its COVID- 19 policy. Librandi, proceeding pro se, filed suit against Alexion alleging that its COVID-19 policy violated the Americans with Disabilities Act (“ADA”), 42 U.S.C. § 12101 et seq. Specifically, she claims that under its COVID-19 policy, Alexion "regarded her as disabled with a contagious disease with an impaired immune system" and that Alexion "made a record of such disability." Am. Compl., Count 1; ECF No. 9 ¶¶ 13, 46. She also alleges that Alexion retaliated against her "by seeking to impose its 'Covid-19 Policy' upon [her]." Count 2; Id. ¶ 156. Alexion has moved to dismiss the complaint for failure to state a claim under Fed. R. Civ. P. 12(b)(6). ECF No. 26. I have carefully considered the complaint and its attachments and the parties' briefs, and I find that oral argument will not aid the decisional process. For the reasons that follow, the motion to dismiss is granted. I. BACKGROUND1 Librandi was employed by Alexion from June 2008 until September 14, 2022. ECF No. 9 ¶ 27. In July 2021, Alexion was acquired by AstraZeneca. Id. ¶ 28. In August 2021, Alexion implemented a COVID-19 policy. Id.; ECF No. 9-1 at 2. In a memorandum to employees, Alexion stated that as part of its "return to the workplace" plan, employees would be required to be

vaccinated against COVID-19. ECF No. 9-1 at 2. Alexion would provide accommodations for employees who were unable to be vaccinated due to medical, religious, or other restrictions. Those employees would be required to test weekly for COVID-19. Id. Alexion instructed employees to disclose their vaccination status by September 3, 2021. ECF No. 9 ¶ 29; ECF No. 9-1 at 9. Librandi opposed Alexion's COVID-19 policy "partly because the practices were unrelated to the performance of her essential job functions."2 ECF No. 9 ¶ 24. She "made inquiries regarding the protections a 'religious exemption' would give her against [Alexion's] COVID-19 policy." Id. ¶ 31. She also was concerned about the security of her health information because she had to send many emails outside the "supposedly secure" portal being used to collect vaccination information.

Id. ¶ 32. She completed a form requesting a religious accommodation "related to vaccination or disclosure of vaccination status." ECF No. 9-1 at 19. On December 21, 2021, Alexion notified Librandi that it would exempt her until January 21, 2022 from its requirement that she provide proof of vaccination, complete weekly PCR testing, and wear a mask "so long as [she] conduct[ed] all work fully remotely." ECF No. 9-1 at 27. Alexion told her that it "cannot agree to an accommodation allowing in-person interactions in your capacity as an Alexion employee without

1 The facts, which I accept as true for the purposes of this motion, are drawn from the amended complaint (ECF No. 9), the attached exhibits, and the documents incorporated by reference in the complaint. Tellabs, Inc. v. Makor Issues & Rts., Ltd., 551 U.S. 308, 322 (2007) (On a Rule 12(b)(6) motion to dismiss, a court “must consider the complaint in its entirety, as well as other sources courts ordinarily examine when ruling on [such a motion], in particular, documents incorporated into the complaint by reference, and matters of which a court may take judicial notice.” ) 2 Librandi claims that the vaccination requirement is illogical, ECF No. 9 ¶ 126, and that the vaccines are experimental. Id. ¶ 106. See ECF No. 36 at 22-23. I need not address these assertions to resolve the pending motion. compliance with Alexion's vaccination, masking, or testing requirements." Id. Alexion subsequently extended the work from home requirement through February 21, 2022 and then through April 30, 2022. ECF No. 9 ¶ 37. In March and April 2022, because she was not permitted to be on site, Librandi missed team meetings and work-related social gatherings, which had a negative impact on her career advancement. Id. ¶ 38.

On May 6, 2022, Alexion notified Librandi that "[w]orking fully remotely is no longer feasible and you may not come on-site as an unvaccinated employee unless you maintain compliance with weekly PCR testing obligations." ECF No. 9-1 at 31. Alexion instructed her to "begin reporting to [her] assigned site location regularly beginning June 6, 2022." Id. at 32. On May 19, 2022, Librandi wrote a letter to Alexion that stated in pertinent part:

I am documenting that Alexion Pharmaceuticals (Alexion) is regarding me as having a disability (an impaired immune system and an impaired respiratory system) without any diagnosis or individualized assessment and has also made a record of such disability by mis-classifying me as having, in ADA terms, a mental or physical impairment that substantially limits one or more major life activities. Alexion is also coercing me to submit to medical examinations and interventions as accommodations ("mitigation measures") without any informed consent. It has been extremely difficult to perform my employment duties because of these interruptions and harassment. . . .

Regarding the mitigation measures such as vaccines and submitting to medical examinations, I am not required to accept these or any mitigation measures under Title I of the ADA 29 CFR Part 1630.9(d)…. My employer is responding to me as if I have an actual or potential contagious disease. I demand to review the records the employer has relied upon to determine that I am a direct threat. If there is some legal authority that overrides my rights under the ADA, please provide me with a legal citation…. Because Alexion is regarding me as disabled, I am invoking my rights under the Americans with Disabilities Act as a qualified individual with a disability.

ECF No. 9-1 at 34. In a second letter to Alexion, also dated May 19, 2022, Librandi wrote: Alexion regards me as disabled with an impaired immune system and an impaired respiratory system. I have been given the coercive, threatening, and intimidating choice to be tested or suffer adverse employment action, which clearly shows that my employer regards me as disabled by classifying me as a potential or actual source of COVID-19. Alexion regards me as disabled through its classification of me as unvaccinated, and the affirming action of regarding me as unvaccinated is that I will suffer adverse employment action if I don't comply with its testing accommodation. These factors are based solely upon my employer[']s perception of my physical condition.

ECF No. 9-1 at 38-39. Librandi stated she was "withdrawing [her] request for religious exemption" and "claiming [her] rights under the ADA." Id. at 39.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Tellabs, Inc. v. Makor Issues & Rights, Ltd.
551 U.S. 308 (Supreme Court, 2007)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Thompson v. Carter
284 F.3d 411 (Second Circuit, 2002)
Walker v. Schult
717 F.3d 119 (Second Circuit, 2013)
Caskey v. County of Ontario
560 F. App'x 57 (Second Circuit, 2014)
Mastafa v. Chevron Corp.
770 F.3d 170 (Second Circuit, 2014)
Davis v. New York City Department of Education
804 F.3d 231 (Second Circuit, 2015)
Darby v. Greenman
14 F.4th 124 (Second Circuit, 2021)
Terry v. Incorporated Village of Patchogue
826 F.3d 631 (Second Circuit, 2016)

Cite This Page — Counsel Stack

Bluebook (online)
Librandi v. Alexion Pharmaceuticals Inc, Counsel Stack Legal Research, https://law.counselstack.com/opinion/librandi-v-alexion-pharmaceuticals-inc-ctd-2023.